story of the week
AACR 2021: Addition of Nivolumab to Neoadjuvant Chemotherapy Increases Pathologic Complete Response to Non-Small Cell Lung Cancer
Findings are among first to demonstrate benefits of neoadjuvant immunotherapy plus chemotherapy for resectable disease
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.